Immunome, Inc. (IMNM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The ...

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.21%. A quarter ago, it was expected that this company would post a loss of $0.68 per share when it actually produced a loss of $0.84, delivering a surprise of -23.53%.Over the last four quarters, the company has surpasse ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39580 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0694340 (State or oth ...

Financial Performance - As of March 31, 2025, Immunome reported cash, cash equivalents, and marketable securities totaling $317.3 million, including net proceeds of $161.7 million from a financing round in January 2025[9]. - Immunome reported a net loss of $41.6 million for Q1 2025, compared to a net loss of $129.5 million in Q1 2024[9][13]. - Collaboration revenue for Q1 2025 was $2.9 million, up from $1.0 million in Q1 2024[13]. - The total operating expenses for Q1 2025 were $47.6 million, significantly lower than $133.3 million in Q1 2024[13]. - Research and development expenses for Q1 2025 were $36.9 million, with stock-based compensation costs of $2.4 million[9]. - General and administrative expenses for Q1 2025 were $10.7 million, including stock-based compensation expense of $3.3 million[9]. - The weighted-average shares outstanding for Q1 2025 were 79,410,354, compared to 51,544,383 in Q1 2024[13]. Clinical Development - The Phase 3 RINGSIDE Part B study of varegacestat for desmoid tumors completed full enrollment in February 2024, with topline data expected in the second half of 2025[3]. - The Phase 1 clinical trial of IM-1021 began dosing its first patient in February 2025, targeting advanced B-cell lymphomas and solid tumors[4]. - Immunome received IND clearance for IM-3050 in April 2025 and plans to initiate a Phase 1 clinical trial in the second half of 2025[4].

Shares of Immunome, Inc. (IMNM) have gained 19.7% over the past four weeks to close the last trading session at $7.43, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $26 indicates a potential upside of 249.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $6.26. While the lowest estimate of $20 indicates a 169.2% increase from the curren ...

Group 1 - Immunome (NASDAQ: IMNM) is recognized for its unique approach to antibody discovery and strategic pipeline expansion, particularly in oncology [1] - The company is positioned in a high-growth sector, with a focus on disruptive technologies and innovation, which are expected to yield substantial returns [1] Group 2 - The analysis emphasizes a combination of fundamental analysis and future trend prediction as key components of investment strategy [1]

Company Performance - Immunome, Inc. reported a quarterly loss of $0.84 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.68, and compared to a loss of $0.54 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $2.74 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 10.81%, and down from $3.83 million in the same quarter last year [2] - Over the last four quarters, Immunome has only surpassed consensus EPS estimates once and has consistently missed revenue estimates [2] Stock Performance - Immunome shares have declined approximately 21.3% since the beginning of the year, contrasting with the S&P 500's decline of 4.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.75 on revenues of $2.33 million, and for the current fiscal year, it is -$3.13 on revenues of $9.33 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Immunome belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Immunome's stock performance [5]

Clinical Development - Varegacestat demonstrated an objective response rate (ORR) of 75% in evaluable patients and 64% in the intent-to-treat population during the Phase 2 RINGSIDE study, with a median reduction in tumor volume of 88%[515]. - The Phase 3 registrational trial for Varegacestat was completed in February 2024, with topline data expected in the second half of 2025[516]. - IM-1021, a ROR1 antibody-drug conjugate, received FDA clearance in December 2024, with the Phase 1 trial ongoing and the first patient dosed in February 2025[512]. - IM-3050, a fibroblast activation protein-targeted radioligand therapy, is designed to treat solid tumors and has an IND submitted to the FDA in March 2025, with a Phase 1 trial expected to start in the second half of 2025[518]. - The company is advancing a pipeline comprising two clinical assets and four preclinical assets, focusing on targeted therapies for cancer patients[511]. - The company has six additional antibody-drug conjugates currently undergoing lead optimization for future development decisions[513]. Financial Performance - Net loss for 2024 was $293.0 million, compared to a net loss of $106.8 million in 2023, reflecting significant operating losses[551]. - Collaboration revenue decreased by $5.0 million, from $14.0 million in 2023 to $9.0 million in 2024, primarily due to reduced research and development activities allocated to AbbVie[541]. - In-process research and development expenses increased by $71.5 million, from $80.8 million in 2023 to $152.3 million in 2024, mainly related to the write-off of acquired IPR&D assets[540]. - Research and development expenses surged by $106.5 million, from $23.1 million in 2023 to $129.5 million in 2024, driven by increased activities for multiple product candidates[543]. - General and administrative expenses rose by $13.3 million, from $19.7 million in 2023 to $33.0 million in 2024, largely due to increased personnel-related costs[546]. - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future[530]. - The company incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future[655]. Cash Flow and Financing - Net cash used in operating activities for the year ended December 31, 2024 was $110.8 million, primarily due to a net loss of $293.0 million, offset by noncash charges of $167.3 million[556]. - Net cash provided by financing activities for 2024 was $240.5 million, including $230.0 million from the 2024 Financing and $20.0 million from the issuance of common stock[559]. - The company raised $230,002,000 from a public offering in 2024[647]. - Existing cash and marketable securities, along with proceeds from the 2025 Financing, are expected to fund operations for at least 12 months from the filing date of the Annual Report[562]. - The company plans to finance cash needs through equity offerings, debt financings, and collaborations, amid potential market volatility[566]. Governance and Compliance - The board of directors' audit committee oversees cybersecurity risk management processes, ensuring integration into overall risk management[496]. - The company has adopted a Code of Business Conduct and Ethics applicable to all officers, directors, and employees, ensuring compliance with SEC rules[606]. - Management assessed the effectiveness of internal control over financial reporting and concluded it was effective as of December 31, 2024[593]. - The company has established a robust governance framework, including an insider trading policy, to safeguard shareholder interests and maintain market integrity[19.1]. Stockholder Information - As of March 14, 2025, there were approximately 63 record holders of the company's common stock, with a significantly greater number of beneficial owners[505]. - The company has not declared or paid any dividends since inception and does not expect to do so in the foreseeable future[506]. - The company reported a weighted-average shares outstanding of 58,639,441 in 2024, significantly higher than 19,843,651 in 2023, an increase of 195.5%[643]. Asset Management - Total assets increased to $240,241,000 in 2024 from $148,540,000 in 2023, representing a growth of 61.6%[641]. - Cash and cash equivalents at the end of 2024 were $143,351,000, up from $98,679,000 at the end of 2023, an increase of 45.1%[647]. - The company has made significant amendments to its equity incentive plans, which may impact future employee compensation and retention strategies[10.2]. Research and Development - Research and development expenses include costs for salaries, clinical trials, and contracted services, which are expensed as incurred[678]. - The company has not experienced any material differences between accrued costs and actual costs incurred for research and development activities[680]. - Immunome's share-based compensation program allows for grants of stock options and restricted stock awards, with expenses recognized over the vesting period[681].

Exhibit 99.1 Immunome Reports Full Year 2024 Financial Results and Provides Business Update 3/19/2025 BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in- class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update. "Immunome's efficient execution in 2024 laid the foundation for a productive 2025," said Clay B. Siegall, Ph.D., President and Chief Executive Offi ...

Group 1 - Many biotechs in the antibody-drug conjugate (ADC) space experienced a pullback throughout much of 2024, which offset a rally that occurred in late 2023 and early 2024 [1] - Immunome (NASDAQ: IMNM) was one of the companies affected by this downturn, despite a buy rating issued in April 2024 [1]